lenvatinib and Uterine-Neoplasms

Endometrial cancer is a highly treatable cancer; however, 13 to 15% of cases recur. Traditional cytotoxic chemotherapies have produced modest results, but new treatments show promise. This information was compiled from an extensive literature search, which was completed in order to summarize current data in this review. Our objective was to describe new therapies for recurrent endometrial cancer in the last 5 years.. New targeted therapies are being identified for advanced and recurrent endometrial cancer. Within the last 5 years, pembrolizumab and lenvatinib have improved survival in advanced or recurrent endometrial cancer. Similarly, trastuzumab has shown efficacy in HER2-producing uterine serous cancer. Patients with recurrent endometrial cancer are often difficult to salvage. Traditional chemotherapy has produced poor response rates. Both immunotherapy and other targeted therapies have shown promise in recurrent disease.

Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunotherapy; Molecular Targeted Therapy; Phenylurea Compounds; Quinolines; Trastuzumab; Uterine Neoplasms

Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer. Multimodality treatment with surgery, radiotherapy, and chemotherapy is commonly used, given its propensity for extrauterine spread, distant recurrences, and poor prognosis. However, the use of molecularly-based therapy is expanding. Here, we review key molecular features of USC, discuss current management, and assess the landscape of novel therapies and combinations.

Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Female; Humans; Molecular Targeted Therapy; Mutation; Phenylurea Compounds; Quinolines; Randomized Controlled Trials as Topic; Trastuzumab; Tumor Suppressor Protein p53; Uterine Neoplasms

Topics: Aged; Air; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Endometrial Neoplasms; Female; Humans; Phenylurea Compounds; Quinolines; Uterine Neoplasms